A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure

Trial Profile

A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Oct 2016

At a glance

  • Drugs Piclidenoson (Primary)
  • Indications Ocular hypertension; Open-angle glaucoma
  • Focus Therapeutic Use
  • Sponsors Can-Fite BioPharma
  • Most Recent Events

    • 20 Oct 2016 This trial was completed in Bulgaria (end date: 2016-02-22), according to European Clinical Trials Database.
    • 05 Jul 2016 Results published in a Can-Fite BioPharma media release.
    • 05 Jul 2016 Primary endpoint (Intraocular pressure) has not been met, according to a Can-Fite BioPharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top